Multidrug-resistant Acinetobacter baumannii infection has recently emerged as a worldwide 27 clinical problem and colistin is increasingly being used as last resort therapy. Despite its 28 favorable bacterial killing, resistance and heteroresistance to colistin have been described. 29 Mutations in the PmrAB regulatory pathway have been already associated with colistin 30 resistance whereas the mechanisms for heteroresistance remain largely unknown. The purpose 31 of the present study is to investigate the role of PmrAB in laboratory-selected mutants 32 representative of global epidemic strains. During brief colistin exposure, colistin resistant and 33 colistin heteroresistant mutants were selected in a one-step strategy. Population Analysis 34 Profiling (PAP) was performed to confirm the suspected phenotype. Upon withdrawal of 35 selective pressure, compensatory mutations were evaluated in another one-step strategy. A 36 trans-complementation assay was designed to delineate the involvement of the PmrAB 37 regulatory system using qPCR and PAP. Mutations in the PmrAB regulatory pathway were 38 associated with colistin resistance and colistin heteroresistance as well. The trans-39 complementation assay provides a proof for the role played by changes in the PmrAB regulatory 40 pathway. The level of colistin resistance is correlated to the level of expression of pmrC. The 41 resistance phenotype was partially restored since the complemented strain became 42 heteroresistant. This report shows the role of different mutations in the PmrAB regulatory 43 pathway and warns on the development of colistin heteroresistance that could be present but 44 not easily detected with routine testing.
Introduction
Acinetobacter baumannii has emerged as an opportunistic and medically important pathogen 48 causing a broad range of nosocomial infections, particularly amongst the most vulnerable 49 patients in the intensive care units. The most frequent infections are ventilator-associated Mutants associated with colistin resistance and heteroresistance. To verify whether there 149 was an association between mutants and the PmrAB regulatory pathway, it was decided to 150 quantify the level of transcripts of previously described genes in longitudinally derived isolates. 151 The aim was to study if one of these genes had a distinct expression according to the 152 susceptibility to colistin (susceptible, heteroresistant, resistant) . As expected, the expression of 153 the transcripts of the pmrCAB operon increased both, in colistin resistant and colistin 154 heteroresistant mutants ( Fig. 1D-F) . Unexpectedly, the level of transcripts of pmrC were highly 155 similar in colistin-resistant and colistin-heteroresistant strains derived from Ab2 (Fig. 1E ). The 156 role of colistin as an inducer of the expression of the transcripts of the pmrCAB operon was 157 checked. Two stress concentrations of colistin (0.25 mg/L and 2 mg/L) were tested for Ab2 158 mutants and no induction was observed (data not shown). In isolate Ab2-1-R4-S1, the transcript 159 level of the pmrCAB operon came back to the level observed in the parental clinical isolate 160 confirming the role played by the insertion sequence within the pmrB gene. Furthermore, the 161 transcript level of the pmrC gene remained even lower than the transcript level observed in the 162 parental strain. The expression of the transcripts of eptA showed the same trend as that of the 163 genes present in the pmrCAB operon except that the transcripts of eptA were not constitutively 164 expressed in Ab3 (Fig. 1F ).
165
PmrAB mutants contributed to colistin resistance and colistin heteroresistance. To check 166 if amino acid substitutions identified by Sanger sequencing contributed to colistin resistance or 167 heteroresistance, isolate Ab2 was complemented in trans with the wild-type and mutated 168 pmrAB genes. Complementation of isolate Ab2 with the wild-type pmrAB genes did not alter 169 the susceptibility to colistin ( Fig. 2A ). Complementation with a heteroresistant mutant or a 170 disrupted mutant did not alter the susceptibility to colistin ( Fig. 2A ). Colistin resistance was 171 only partially restored when isolate Ab2 was complemented with pmrAB(Ab2-1-R4).
172
Complementation with a resistant mutant resulted in colistin heteroresistance ( Fig. 2A) . The 173 level of transcripts of the pmrA and pmrB genes in transformants complemented in trans with 174 the wild-type and mutated pmrAB genes were equally upregulated ( Fig. 2B ). These results 175 indicate that wild-type and mutated pmrAB genes were actually cloned with their own promoter.
176
The level of transcripts of the pmrC gene was up-regulated for the resistant-and the Heteroresistance is a phenomenon where subpopulations of seemingly isogenic bacteria exhibit 188 a range of susceptibilities to a particular antibiotic. Heteroresistance can be intrinsic or acquired.
189
In this study, colistin heteroresistance as well as colistin resistance were acquired through 190 mutations in the PmrAB regulatory pathway. The trans-complementation assay demonstrated 191 the role played by this two-component system and showed a direct correlation between 192 expression of pmrC and colistin (hetero)resistance.
193
The one-step selection strategy generated both resistant and heteroresistant isolates. All 194 mutations described in this study have been previously observed in clinical or laboratory strains 195 except the two heteroresistant mutants derived from isolate Ab1 where a 12 base pair insertion 196 or a M308R amino acid substitution were observed in pmrB. The fact that these two mutants 197 had not been observed yet could be due to the process of selection for spontaneous mutation production chosen by the other authors (7, 8, 15, 16) . The authors favored serial gradient observed in a case-study (25). To explain the low prevalence of colistin resistance, the 222 hypothesis of heteroresistance could not be ruled out. Two animal-based studies proved that K. 223 pneumoniae and E. cloacae displaying undetected colistin heteroresistance could lead to 224 treatment failure in murine infection (26, 27) . Heteroresistance might be an alternative to the 225 costly colistin resistance. A transcriptome remodelling has been portrayed during infection and 226 treatment and a convergent change was observed for clinical isolates with pmrAB mutations 227 (28). Most isolates originated from patients treated with colistin. All of the isolates were 228 susceptible to colistin at an MIC of 0.5 mg/mL and had a differential expression of pmrC that 229 is consistent with heteroresistance. In addition, this study allowed to more strictly define the 230 Pmr regulon in agreement with a precedent transcriptomic study (29) . The PmrAB two-231 component regulatory system facilitates adaptation to diverse environments in many Gram-232 negative bacteria (30). The use of CAMPs may confer a cross-resistance to host CAMPs and 233 the A. baumannii PmrAB two-component regulatory system could be the culprit (31).
234
Heteroresistance due to pmrAB mutations may also have implications on immunogenicity. In 235 Francisella tularensis, flmK leads to addition of galactosamine to lipid A and its inactivation 236 provided protective immunity (32). The galactosamine modification of lipid A has been 237 described in Acinetobacter baumannii as well (33).
238
Therapeutic concentrations of colistin range from 2 to 4 mg/L in patients (34). Concentrations 239 to prevent the selection of resistant mutants are considerably higher than therapeutic 240 concentrations (35). It is not surprising that the rate of heteroresistance can vary from 18.7% to 241 100% (36). Disk diffusion or MIC gradient strips assays are typically used as screening methods 242 (14). They might miss the heteroresistant phenotype because of the low bacterial load used in 243 these methods, a load that is inappropriate to detect the (low) frequency resistant subpopulation. Germany) for 1 min and the lysate was centrifuged at 3500g for 3 min. Five µL of hundred-288 fold diluted supernatant were directly used for PCR of the entire pmrCAB operon using 289 previously described primers (Table 3 ). The PCR products were purified using QIAquick PCR 290 purification kit (Qiagen, Hilden, Germany) following supplier instructions and eluted in 30 µL 291 of pure water. Both strands were completely sequenced with Big Dye V3.1 on a 3730XL DNA 292 Analyzer (Life Technologies, Carlsbad, CA) using the same primers as were used for 293 amplification (Table 3) .
294
Population Analysis Profiling (PAP) 295 Response to colistin in selected mutants was determined by PAP using a modified spotting 296 method (43). Briefly, a suspension of each strain was adjusted to 2.0 McFarland and serially alone and on a two-fold series of colistin-containing plates from 0.25 to 16 mg/L. Isolate Ab3 299 and mutants were streaked on MH alone and on a two-fold series of colistin-containing plates 300 from 0,5 to 8 mg/L. For each condition, four 10-µL droplets of the four highest concentrations 301 were spotted on one plate and four 10-µL droplets of the lowest concentrations were spotted on 302 a second plate. Colonies were counted after 24h incubation at 37°C. Three biological replicates 303 were performed. Heteroresistance was considered when the antibiotic exhibiting the highest 304 inhibitory effect was >8-fold higher than the highest non-inhibitory concentration (14). 306 The selected clinical isolates and mutants were grown to the mid-logarithmic phase in cation- was used to determine whether transcript levels from a gene differed among the transformants.
305

RT-qPCR experiments
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* refers to P < 0.05, ** refers to P < 0.01, *** refers to P < 0.001. 
